Autonomic Dysfunction, Myocardial Infarction
Conditions
Keywords
Heart rate variability, Percutaneous coronary intervention, Drug-eluting stents, Risk assessment, Prognosis, Major adverse cardiovascular events, Left ventricular ejection fraction, Secondary prevention
Brief summary
Aims * heart rate variability (HRV) assessment in patients with acute myocardial infarction who undergo primary percutaneous coronary intervention (PCI); * measurement of HRV using a device approved for medical use in Europe; * assessment of the correlation between HRV and short- and long-term adverse cardiovascular events (composite of all-cause mortality and major adverse cardiovascular events - MACE; ventricular arrhythmias; hospital admissions for heart failure; left ventricular systolic and diastolic disfunction; MACE in special subgroups of patients - elderly, diabetes mellitus, chronic kidney disease) in patients treated by primary PCI for acute myocardial infarction; * creating a registry of HRV parameters measured in a contemporary cohort of patients with acute myocardial infarction.
Detailed description
The following data will be collected: * general demographic data; * time from chest pain onset to primary PCI; * comorbidities (ischemic heart disease, arterial hypertension, previous PCI or coronary artery bypass surgery - CABG, heart failure, peripheral artery disease, atrial fibrillation, stroke, diabetes mellitus, kidney disease); * cardiovascular risk factors (age, body mass index, smoking, abdominal perimeter, sedentarism, gender, inflammation); * cardiac rhythm derived from electrocardiographic data; * HRV time- and frequency domain parameters (respectively, SDNN, SDANN, RMSSD and LF, HF, LF/HF ratio); * routine biological data and biomarkers, including creatine kinase-MB (CK-MB), aspartate transaminase (AST), lactate dehydrogenase (LDH) and cardiac-specific troponin; * left ventricular ejection fraction at admission, at discharge and at follow-up (1 month, 6 months and 1 year); * initial and final thrombolysis in myocardial infarction (TIMI) flow; * type of stent used for coronary angioplasty; * Global Registry of Acute Coronary Events (GRACE) score; * SYNTAX score II in case of three-vessel coronary disease or involving left main stem; * in-hospital, one month and long-term clinical outcomes (composite of all-cause mortality and major adverse cardiovascular events - MACE; ventricular arrhythmias; hospital admissions for heart failure; left ventricular systolic and diastolic disfunction; MACE in special subgroups of patients - elderly, diabetes mellitus, chronic kidney disease).
Interventions
PROCEDUREHeart rate variability measurement
HRV will be measured at the moment of patients' admission to the cardiac catheterization laboratory on the top of therapy guided by European guidelines. Both, time- and frequency-domain parameters (respectively, SDNN, SDANN, RMSSD and LF, HF, LF/HF ratio) of the HRV will be obtained using a validated medical device during 5-minute segments before and after revascularization of the culprit artery. In addition, HRV will be evaluated in ambulatory setting, at 1 month and at 6 months after the index event. Obtained interbeat interval data will be further analysed using a dedicated software in order to derive specified HRV parameters.
PROCEDUREPercutaneous coronary intervention
Coronary angiography and PCI will be performed using femoral or radial approach after local anesthetic infiltration with Lidocaine and arterial sheath placement. Following the culprit lesion detection and guidewire placement, thromboaspiration and glycoprotein IIb/IIIa inhibitors will be left to the operator decision. Also, the choice of coronary stenting technique and stent sizing will be performed according to the operator experience. Antiplatelet and anticoagulant drugs will be administered in concordance with latest European guidelines.
Sponsors
Grigore T. Popa University of Medicine and Pharmacy
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients with ST-Elevation Myocardial Infarction (STEMI) treated with primary PCI within 12 hours from symptoms onset; * patients in sinus rhythm; * patients who have read and signed the standard informed consent regarding enrolment in the study.
Exclusion criteria
* unconscious or intubated patients who are unable to sign the standard informed consent; * patients with atrial fibrillation; * patients with sinus node dysfunction or atrioventricular block of any degree; * frequent premature supraventricular or ventricular contractions; * paced ventricular rhythm; * patients treated with positive inotropic and chronotropic drugs; * history of myocardial infarction or myocardial revascularization (PCI or CABG); * patients refusal.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite of all-cause mortality and major adverse cardiovascular events (MACE) | in-hospital, 1 month and 1 year | MACE will be defined as cardiac mortality, fatal and non-fatal myocardial infarction, unplanned target vessel revascularization and stroke) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiac mortality | in-hospital, 1 month and 1 year | Defined as number of deaths due to cardiac causes |
| All-cause mortality | in-hospital, 1 month and 1 year | Defined as total number of deaths from any cause |
| Fatal and non-fatal myocardial infarction | in-hospital, 1 month and 1 year | Defined as a new myocardial infarction |
| Target vessel revascularization | in-hospital, 1 month and 1 year | Defined as unplanned PCI or coronary artery bypass graft surgery for a stenosis in another part of the vessel treated at the index PCI |
| Target lesion revascularization | in-hospital, 1 month and 1 year | Defined as repeat PCI or coronary artery bypass graft surgery of the target lesion treated at the index PCI |
| Stroke | in-hospital, 1 month and 1 year | Defined as ischemic or hemorrhagic stroke |
Other
| Measure | Time frame | Description |
|---|---|---|
| Left ventricular ejection fraction (LVEF) | in-hospital, 1 month and 1 year | Appraised using two-dimensional transthoracic echocardiography - Simpsons method |
| Left ventricular diastolic dysfunction | in-hospital, 1 month and 1 year | Appraised using two-dimensional transthoracic echocardiography - E/A and E/e prime ratios |
| Composite of all-cause mortality and major adverse cardiovascular events in special subgroup of patients | in-hospital, 1 month and 1 year | elderly, diabetes mellitus, chronic kidney disease |
| Ventricular arrhythmias | in-hospital, 1 month and 1 year | Defined as electrocardiographic documentation of ventricular fibrillation or sustained ventricular tachycardia |
| Hospital admissions for heart failure | 1 year | Defined as any subsequent admission for a primary diagnosis of heart failure |
Countries
Romania
Contacts
Primary ContactAlexandru Burlacu, MD, PhD
Backup ContactCrischentian Brinza, MD
Outcome results
None listed